Mylan Inc plans to sell up to 92 million shares in Indian drugmaker Biocon Ltd, worth up to 34.81 billion Indian rupees ($363 million), according to a term sheet seen by Reuters.
India watches Hormuz for oil and gas. These four sea passages decide prices of many other things
Is the weak monsoon now also a power-sector worry?
KYB and KYC: Every stock has a business behind it
The Eveready story: From ‘Give Me Red’ to staying relevant after 120 years
Why is the price of silver falling? The answer: It has cousins. Part 2 – The maternal cousin
Mylan, part of Viatris, exits Biocon by selling its 5.64% stake for ₹3,679 crore. Domestic mutual funds and global investors buy…
Biocon shares experienced a significant jump of over 6% on Tuesday. Viatris-owned Mylan intends to sell a substantial stake,…
Mylan sold a ₹1,839 crore stake in Biocon through a block deal, attracting strong institutional demand. ICICI Prudential Mutual…
Weak monsoon may boost soluble fertilizer demand, but soaring prices pose a significant risk, warns SFAI President Rajib…
There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a…
Discover key stocks to watch, including Biocon and Grasim, amid significant market developments and acquisitions this Tuesday.
